Get started
Author

Philip A. Dy

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2013 · Nitin Jain, Emily Curran, et al. · Clinical Cancer Research · 115
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622
2016 · Anne F. Schott, William E. Barlow, et al. · Breast Cancer Research and Treatment · 63
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2020 · Andrew M. Evens, Fangxin Hong, et al. · Clinical Cancer Research · 22
Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group
2011 · Priya Rastogi, Marc E. Buyse, et al. · Clinical Breast Cancer · 20
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
2021 · Halle C.F. Moore, William E. Barlow, et al. · Clinical Cancer Research · 10
PDF
Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).
2012 · Nitin Jain, Emily Curran, et al. · Journal of Clinical Oncology · 7
A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group
2017 · Andrew M. Evens, Fangxin Hong, et al. · Blood · 5
Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group
2009 · P. Rastogi, M. Buyse, et al. · Journal of Clinical Oncology · 3
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study
2020 · Giselle K. Perez, Fangxin Hong, et al. · Blood · 1
Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
PDF
Supplemental Tables 1-9 from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2023 · Andrew M. Evens, Fangxin Hong, et al.
Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
2023 · Halle C.F. Moore, William E. Barlow, et al.
Data from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2023 · Andrew M. Evens, Fangxin Hong, et al.
Data from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
Data from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2023 · Andrew M. Evens, Fangxin Hong, et al.
Data from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
2023 · Halle C.F. Moore, William E. Barlow, et al.
Supplementary Figure from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
2023 · Halle C.F. Moore, William E. Barlow, et al.
Data from A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
2023 · Halle C.F. Moore, William E. Barlow, et al.
Data from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
2023 · Nitin Jain, Emily Curran, et al.
PDF
Supplemental Tables 1-9 from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2023 · Andrew M. Evens, Fangxin Hong, et al.
Works count: 23
Citation count: 246
H-index: 6
I10-index: 5
Year
Topic
Type